Posted Date : May 27,2020
Product (RFP/RFQ/RFI/Solicitation/Tender/Bid Etc.) ID : SW-33981
Government Authority located in Arkansas; USA based organization looking for expert vendor for high content imaging system.
[A] Budget: Looking for proposal
[B] Scope of Service:
Vendor needs to provide high content imaging system to perform measurements of intracellular calcium (Ca2+) flux in human donor induced-pluripotent stem cell (iPSCs) cardiomyocytes to acquire more knowledge on molecular changes in the heart to understand the mechanisms underlying cardiotoxicity induced by drugs such as anti-cancer drugs, anthracyclines.
1. Widefield imaging capabilities with confocal imaging with >3 log dynamic range to capture variability in fluorescent intensity that will be indicative of cytotoxicity and mitochondrial integrity related to cardiotoxicity following treatment with anthracyclines on human-derived iPSC cardiomyocytes. 2. Objectives from 1X to 100X magnification to visualize the synchronous beating of the cardiomyocyte monolayer and assessment of uniformity within the cell culture as well as fluorescent intensity inter-cellularly within a specific treatment well. 3. A fully automated X-Y and Z stages with resolution better than 100 nanometers to observe unique morphological changes of the cardiomyocytes during assays measuring Ca2+ flux. 4. The ability to acquire from a variety of multi-well plate formats up to 1,536 wells for high-throughput including unusual formats developed for 3D assays with round bottom for spheroid formation of cardiomyocytes during specific chemical treatments or transwell plates for the promotion of a uniform monolayer of cells and formation of cardiomyocyte morphology. The format flexibility allows the ability to investigate multiple conditions with multiple anthracyclines across variable dosages simultaneously. 5. The capabilities for analyzing beat patterns and monitor changes in intracellular Ca2+ flux associated with human iPSC derived cardiomyocyte contractions. 6. The capabilities for a real-time kinetic cellular screening system for identifying early leads into candidate anthracyclines to further investigate severe adverse effects of delayed-onset cardiotoxicity. 7. The integrated fluidics with a single channel pipettor capable of dispensing compounds into the well and imaging simultaneously to capture a fast Ca+ response window before, during, and after treatment with the compounds. This data capture will provide unique insight to the understanding of anthracycline metabolism through the entire duration of metabolite formation, uptake, and elimination. 8. The capability to give 100 data points per beat (1s) allowing for better peak analysis. This comprehensive analysis will allow for a level of precision necessary to determine onset of effects during anthracycline treatment and evaluate acute versus longer term observations. 9. High Content Image Analysis software tools specifically for Cardiomyocytes to address the translation of preclinical findings demonstrated in our lab of significant decline in heart function and structure in a rodent model to human cardiomyocytes which will be crucial in understanding the molecular basis underlying late-onset anthracycline-induced cardiotoxicity. The ability to investigate the molecular changes in vitro using human donor induced pluripotent stem cells (iPSCs) cardiomyocytes will be an invaluable tool in bridging the knowledge gap from our pre-clinical findings to clinical translation. 10. The capability to provide temporal response curves to analyze and visualize the effect of compounds on beating cells as well as the ability to calculate signal peak parameters based on a dynamic threshold and derivative analysis, and provide amplitude, time, frequency, rate, and width values. These multi-parametric measurements will provide a truly comprehensive assessment of anthracycline treatment effects on intracellular Ca2+ flux and contractility of the human-induced iPSC cardiomyocytes. 11. One-year warranty beginning from date of acceptance. 12. Installation and training.
[C] Eligibility:
- Onshore (USA Organization Only);
[D] Work Performance:
Performance of the work will be Offsite. Vendor needs to carry work in their office location.
Budget :
Deadline to Submit Proposals: June 02,2020
Cost to Download This RFP/RFQ/RFI/Solicitation/Tender/Bid Document : 5 US$
![]()
Product (RFP/RFQ/RFI/Solicitation/Tender/Bid Etc.) ID : SW-33981
Government Authority located in Arkansas; USA based organization looking for expert vendor for high content imaging system.
[A] Budget: Looking for proposal
[B] Scope of Service:
Vendor needs to provide high content imaging system to perform measurements of intracellular calcium (Ca2+) flux in human donor induced-pluripotent stem cell (iPSCs) cardiomyocytes to acquire more knowledge on molecular changes in the heart to understand the mechanisms underlying cardiotoxicity induced by drugs such as anti-cancer drugs, anthracyclines.
1. Widefield imaging capabilities with confocal imaging with >3 log dynamic range to capture variability in fluorescent intensity that will be indicative of cytotoxicity and mitochondrial integrity related to cardiotoxicity following treatment with anthracyclines on human-derived iPSC cardiomyocytes. 2. Objectives from 1X to 100X magnification to visualize the synchronous beating of the cardiomyocyte monolayer and assessment of uniformity within the cell culture as well as fluorescent intensity inter-cellularly within a specific treatment well. 3. A fully automated X-Y and Z stages with resolution better than 100 nanometers to observe unique morphological changes of the cardiomyocytes during assays measuring Ca2+ flux. 4. The ability to acquire from a variety of multi-well plate formats up to 1,536 wells for high-throughput including unusual formats developed for 3D assays with round bottom for spheroid formation of cardiomyocytes during specific chemical treatments or transwell plates for the promotion of a uniform monolayer of cells and formation of cardiomyocyte morphology. The format flexibility allows the ability to investigate multiple conditions with multiple anthracyclines across variable dosages simultaneously. 5. The capabilities for analyzing beat patterns and monitor changes in intracellular Ca2+ flux associated with human iPSC derived cardiomyocyte contractions. 6. The capabilities for a real-time kinetic cellular screening system for identifying early leads into candidate anthracyclines to further investigate severe adverse effects of delayed-onset cardiotoxicity. 7. The integrated fluidics with a single channel pipettor capable of dispensing compounds into the well and imaging simultaneously to capture a fast Ca+ response window before, during, and after treatment with the compounds. This data capture will provide unique insight to the understanding of anthracycline metabolism through the entire duration of metabolite formation, uptake, and elimination. 8. The capability to give 100 data points per beat (1s) allowing for better peak analysis. This comprehensive analysis will allow for a level of precision necessary to determine onset of effects during anthracycline treatment and evaluate acute versus longer term observations. 9. High Content Image Analysis software tools specifically for Cardiomyocytes to address the translation of preclinical findings demonstrated in our lab of significant decline in heart function and structure in a rodent model to human cardiomyocytes which will be crucial in understanding the molecular basis underlying late-onset anthracycline-induced cardiotoxicity. The ability to investigate the molecular changes in vitro using human donor induced pluripotent stem cells (iPSCs) cardiomyocytes will be an invaluable tool in bridging the knowledge gap from our pre-clinical findings to clinical translation. 10. The capability to provide temporal response curves to analyze and visualize the effect of compounds on beating cells as well as the ability to calculate signal peak parameters based on a dynamic threshold and derivative analysis, and provide amplitude, time, frequency, rate, and width values. These multi-parametric measurements will provide a truly comprehensive assessment of anthracycline treatment effects on intracellular Ca2+ flux and contractility of the human-induced iPSC cardiomyocytes. 11. One-year warranty beginning from date of acceptance. 12. Installation and training.
[C] Eligibility:
- Onshore (USA Organization Only);
[D] Work Performance:
Performance of the work will be Offsite. Vendor needs to carry work in their office location.
Budget :
Deadline to Submit Proposals: June 02,2020
Cost to Download This RFP/RFQ/RFI/Solicitation/Tender/Bid Document : 5 US$